Norgine Ventures com­pletes €3 Million Financing With PulseCath

London. 10 October 2016, 09.00 AM BST. Norgine Ventures announced that it has pro­vid­ed financ­ing of up to €3 mil­lion to PulseCath B.V.. This invest­ment recog­nis­es the unique posi­tion­ing of PulseCath’s car­diac assist devices and the growth poten­tial of the com­pa­ny.
PulseCath, based in the Netherlands, devel­ops and com­mer­cialis­es inno­v­a­tive left ven­tri­cle assist devices. The lead prod­uct, iVAC 2L, is used per­cu­ta­neous­ly and pro­vides haemo­dy­nam­ic sup­port dur­ing car­dio­genic shock or high-risk per­cu­ta­neous coro­nary inter­ven­tions. PulseCath devices have a nov­el design based on pul­satile flow, which is more homoge­nous with the nat­ur­al pump­ing func­tions of the heart. iVAC 2L is CE-marked and com­mer­cialised by Terumo in cer­tain European ter­ri­to­ries.
The fund­ing from Norgine Ventures will enable PulseCath to accel­er­ate its com­mer­cial growth and entry into the US mar­ket.
Norgine Ventures is an enti­ty of the Norgine group.
Peter Stein, CEO at Norgine, said: “We are pleased to invest in PulseCath and there­by sup­port an inno­v­a­tive start-up which deliv­ers a tru­ly dif­fer­en­ti­at­ed prod­uct pro­vid­ing short-term cir­cu­la­to­ry sup­port and can mean­ing­ful­ly improve health­care out­comes for the patients”. He added: “PulseCath’s tech­nol­o­gy has the poten­tial to bring supe­ri­or treat­ment options to more patients due to ease of use and com­pat­i­bil­i­ty with exist­ing oper­at­ing room infra­struc­ture. We hope that increas­ing adop­tion of iVAC devices will con­tribute to real improve­ment in the health­care sys­tems and enable bet­ter treat­ment for patients under­go­ing per­cu­ta­neous coro­nary inter­ven­tions.
Yoram Karmon, PulseCath CEO, said: “Norgine Ventures’ invest­ment will help us accel­er­ate our com­mer­cial growth and fund clin­i­cal stud­ies required for the approval of iVAC 2L in the US’’. He fur­ther added: “This invest­ment is anoth­er val­i­da­tion of our unique tech­nol­o­gy, which enables bet­ter heart sup­port via a safer, per­cu­ta­neous approach and which is cost effec­tive to hos­pi­tals as the device is com­pat­i­ble with a stan­dard IABP con­sole.”

Leave a Reply

Your email address will not be published. Required fields are marked *